Sartopore Evo

Sartopore Evo® represents next-generation sterilizing-grade filtration technology specifically engineered for pharmaceutical and biopharmaceutical applications. The innovative surface-modified polyethersulfone (PES) membrane significantly reduces adsorption of critical components including proteins and excipients such as polysorbate 20 and 80, directly supporting higher process yields and stable drug formulations.

The dual-layer membrane design combines a 0.8 μm pre-filter with a 0.2 μm final filter, delivering exceptional flow rates and filter capacity that surpass traditional PVDF membrane performance. This enhanced efficiency allows for smaller filter elements, reducing both adsorption potential and disposable waste generation.

Engineered for versatility across biopharmaceutical processes, these filters excel in critical applications including monoclonal antibody (mAb) production, adeno-associated virus (AAV)-based therapies, and lipid nanoparticle (LNP) formulations. Available in filtration areas ranging from 4.5 cm² to 2.4 m² with multiple connection options, the product line ensures seamless integration regardless of batch size.

Unlike PVDF alternatives, Sartopore Evo® filters contain no intentionally added PFAS compounds, addressing growing regulatory concerns while maintaining supply chain reliability. The consistent membrane construction across all filter sizes enables predictable scale-up and scale-down procedures, supporting reliable process development from laboratory through commercial production. This technology reduces batch losses due to formulation deviations, directly impacting operational efficiency and compliance with stringent pharmaceutical specifications.